Zymeworks Inc.
Organization details
- Legal name
- Zymeworks Inc.
- Former names
- Zymeworks Delaware Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Middletown
- Headquarters state / province
- Delaware
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ZYME
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001937653
- EIN
- 88-3099146
- Wikidata ID
- Q16968498
Board of directors
-
Alessandra Cesano · DirectorSince 2024
-
Brian N. Cherry · DirectorSince 2026
-
Carlos Campoy · DirectorSince 2023
-
Derek John Michael Miller · DirectorSince 2023
-
Gregory Austin Ciongoli · DirectorSince 2025
-
Hollings Renton · DirectorSince 2023
-
Kelvin Neu · DirectorSince 2023
-
Kenneth Galbraith · Director · Chair & CEOSince 2023
-
Kenneth J. Hillan · DirectorSince 2023
-
Nancy Davidson · DirectorSince 2023
-
Neil Gallagher · DirectorSince 2024
-
Oleg Nodelman · DirectorSince 2025
-
Robert E. Landry · DirectorSince 2025
-
Scott Platshon · DirectorSince 2024
-
Susan Mahony · DirectorSince 2023
-
Troy Cox · DirectorSince 2023
Chief executives
Board connections
9 of this board's directors also sit on 15 other boards. 14 are in the same sector.
-
AnaptysBio Inc. Same sectorvia Hollings Renton and Oleg Nodelman
-
Atara Biotherapeutics Inc. Same sectorvia Brian N. Cherry and Gregory Austin Ciongoli
-
Aktis Oncology Inc. Same sectorvia Oleg Nodelman
-
Assembly Biosciences Inc. Same sectorvia Susan Mahony
-
Axsome Therapeutics Inc. Same sectorvia Susan Mahony
-
Cytokinetics Incorporated Same sectorvia Robert E. Landry
-
Foghorn Therapeutics Inc. Same sectorvia Neil Gallagher
-
Gossamer Bio Inc. Same sectorvia Gregory Austin Ciongoli
-
MapLight Therapeutics Inc. Same sectorvia Troy Cox
-
Nuvation Bio Inc. Same sectorvia Oleg Nodelman
-
Puma Biotechnology Inc Same sectorvia Alessandra Cesano
-
REGENXBIO Inc. Same sectorvia Gregory Austin Ciongoli
- via Troy Cox
-
Standard BioTools Inc. Same sectorvia Troy Cox
-
Summit Therapeutics Inc. Same sectorvia Alessandra Cesano
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $5,031,273
- 11 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 9, 2026 | Schayowitz Adam Officer (EVP, Head of R&D) | Option exercise | +37,037 | — | — |
| Oct 9, 2026 | Schayowitz Adam Officer (EVP, Head of R&D) | Open-market sale | −13,832 | $25.85 | $357,557 |
| Jul 6, 2026 | Hollywood Mark Officer (EVP & Chief Operating Officer) | Grant or award | +939 | $22.22 | $20,865 |
| Jan 12, 2026 | Hollywood Mark Officer (EVP & Chief Operating Officer) | Option exercise | +17,666 | — | — |
| Jan 12, 2026 | Smith Jeffrey T L Officer (EVP & Chief Medical Officer) | Option exercise | +17,666 | — | — |
| Jan 12, 2026 | Moore Paul Andrew Officer (Chief Scientific Officer) | Option exercise | +17,666 | — | — |
| Jan 12, 2026 | Kenneth Galbraith Director, Officer (Chair & CEO) | Option exercise | +64,000 | — | — |
| Jan 12, 2026 | Hollywood Mark Officer (EVP & Chief Operating Officer) | Open-market sale | −6,120 | $22.67 | $138,740 |
| Jan 12, 2026 | Smith Jeffrey T L Officer (EVP & Chief Medical Officer) | Open-market sale | −9,310 | $22.67 | $211,058 |
| Jan 12, 2026 | Moore Paul Andrew Officer (Chief Scientific Officer) | Open-market sale | −9,560 | $22.67 | $216,725 |
| Jan 12, 2026 | Kenneth Galbraith Director, Officer (Chair & CEO) | Open-market sale | −30,424 | $22.67 | $689,712 |
| Jan 6, 2026 | Leone D. Patterson Officer (EVP, Chief Bus & Fin Officer) | Grant or award | +459 | $10.55 | $4,842 |
| Jan 5, 2026 | Smith Jeffrey T L Officer (EVP & Chief Medical Officer) | Option exercise | +20,000 | — | — |
| Jan 5, 2026 | Kenneth Galbraith Director, Officer (Chair & CEO) | Option exercise | +47,668 | — | — |
| Jan 5, 2026 | Moore Paul Andrew Officer (Chief Scientific Officer) | Option exercise | +17,168 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Zymeworks Inc.
Who is the CEO of Zymeworks Inc.?
Kenneth Galbraith is Zymeworks Inc.'s Chair & CEO.
How many directors are on Zymeworks Inc.'s board?
Zymeworks Inc.'s board has 16 directors: Alessandra Cesano, Brian N. Cherry, Carlos Campoy, Derek John Michael Miller, Gregory Austin Ciongoli, Hollings Renton, Kelvin Neu, Kenneth Galbraith, Kenneth J. Hillan, Nancy Davidson and 6 others.
Are Zymeworks Inc. insiders buying or selling shares?
Over the last 12 months, Zymeworks Inc. insiders made no open-market purchases and sold $5.0 million of shares in 11 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="zymeworks-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.